Patient characteristics
| Characteristic . | No. . | % . | Median . | Range . |
|---|---|---|---|---|
| Total no. of patients | 101 | |||
| Age, years | 60 | 28-75 | ||
| Female sex | 55 | 54 | ||
| Myeloma subtype | ||||
| Serum | ||||
| IgG κ | 40 | 40 | ||
| IgG λ | 16 | 16 | ||
| IgA κ | 14 | 14 | ||
| IgA λ | 12 | 12 | ||
| IgM κ | 2 | 2 | ||
| IgD κ | 2 | 2 | ||
| IgD λ | 1 | 1 | ||
| Light chain (urine) | ||||
| κ only | 6 | 6 | ||
| λ only | 7 | 7 | ||
| Biclonal (IgG, IgA, κ) | 1 | 1 | ||
| Nonsecretory | 0 | 0 | ||
| ISS at diagnosis | ||||
| I | 34 | 34 | ||
| II | 29 | 29 | ||
| III | 27 | 27 | ||
| Missing | 11 | 11 | ||
| Durie-Salmon staging at diagnosis | ||||
| I | 20 | 20 | ||
| II | 14 | 14 | ||
| III | 67 | 66 | ||
| Lines of therapy pre-AHSCT | ||||
| 1 | 44 | 44 | ||
| 2 | 35 | 35 | ||
| 3 | 15 | 15 | ||
| >3 | 7 | 7 | ||
| Pre-AHSCT treatment | ||||
| PI/IMiD | 71 | 71 | ||
| PI | 16 | 16 | ||
| IMiD | 12 | 12 | ||
| PI/IMiD/other | 1 | 1 | ||
| Other | 1 | 1 | ||
| Mobilization regimen | ||||
| G-CSF | 23 | 23 | ||
| G-CSF + plerixafor | 77 | 76 | ||
| G-CSF + plerixafor, then cyclophosphamide + G-CSF remobilization | 1 | 1 | ||
| KPS pre-AHSCT | ||||
| 70 | 20 | 19 | ||
| 80 | 52 | 51 | ||
| 90 | 29 | 29 | ||
| Time from diagnosis to AHSCT, months | 10.2 | 0.5-62.1 | ||
| CD34 dose infused, 106/kg | 3.12 | 1.7-9.93 | ||
| TNC dose infused, 108/kg | 4.83 | 1.8-44.14 |
| Characteristic . | No. . | % . | Median . | Range . |
|---|---|---|---|---|
| Total no. of patients | 101 | |||
| Age, years | 60 | 28-75 | ||
| Female sex | 55 | 54 | ||
| Myeloma subtype | ||||
| Serum | ||||
| IgG κ | 40 | 40 | ||
| IgG λ | 16 | 16 | ||
| IgA κ | 14 | 14 | ||
| IgA λ | 12 | 12 | ||
| IgM κ | 2 | 2 | ||
| IgD κ | 2 | 2 | ||
| IgD λ | 1 | 1 | ||
| Light chain (urine) | ||||
| κ only | 6 | 6 | ||
| λ only | 7 | 7 | ||
| Biclonal (IgG, IgA, κ) | 1 | 1 | ||
| Nonsecretory | 0 | 0 | ||
| ISS at diagnosis | ||||
| I | 34 | 34 | ||
| II | 29 | 29 | ||
| III | 27 | 27 | ||
| Missing | 11 | 11 | ||
| Durie-Salmon staging at diagnosis | ||||
| I | 20 | 20 | ||
| II | 14 | 14 | ||
| III | 67 | 66 | ||
| Lines of therapy pre-AHSCT | ||||
| 1 | 44 | 44 | ||
| 2 | 35 | 35 | ||
| 3 | 15 | 15 | ||
| >3 | 7 | 7 | ||
| Pre-AHSCT treatment | ||||
| PI/IMiD | 71 | 71 | ||
| PI | 16 | 16 | ||
| IMiD | 12 | 12 | ||
| PI/IMiD/other | 1 | 1 | ||
| Other | 1 | 1 | ||
| Mobilization regimen | ||||
| G-CSF | 23 | 23 | ||
| G-CSF + plerixafor | 77 | 76 | ||
| G-CSF + plerixafor, then cyclophosphamide + G-CSF remobilization | 1 | 1 | ||
| KPS pre-AHSCT | ||||
| 70 | 20 | 19 | ||
| 80 | 52 | 51 | ||
| 90 | 29 | 29 | ||
| Time from diagnosis to AHSCT, months | 10.2 | 0.5-62.1 | ||
| CD34 dose infused, 106/kg | 3.12 | 1.7-9.93 | ||
| TNC dose infused, 108/kg | 4.83 | 1.8-44.14 |
ISS, International Staging System; KPS, Karnofsky performance status; PI, proteasome inhibitor (only); TNC, total nucleated cells.